Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | CES2 | O00748 | 8/20 | 0.45 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dodecane SCHEMBL28230254 | 1.00 | ALDH1A1 (0.70) | ALDH1A1TDP1CES2CES1EPHX1 | |
| Methyl Isobutyl Ketone SCHEMBL2340589 | 0.97 | ALDH1A1 (0.74) | ALDH1A1TDP1CES2CES1EPHX1 | |
| Methyl Isobutyl Ketone SCHEMBL5000849 | 0.97 | ALDH1A1 (0.74) | ALDH1A1TDP1CES2CES1EPHX1 | |
| Cetyl Alcohol SCHEMBL8391123 | 0.91 | ALDH1A1 (0.58) | ALDH1A1TDP1CES2EPHX1GPR84 | |
| 2-Decanone SCHEMBL10511757 | 0.91 | ALDH1A1 (0.58) | ALDH1A1TDP1CES2CES1GPR84 | |
| Myristyl Alcohol SCHEMBL8390931 | 0.91 | ALDH1A1 (0.58) | ALDH1A1TDP1CES2EPHX1GPR84 | |
| Methyl Isobutyl Ketone SCHEMBL9045794 | 0.89 | ALDH1A1 (0.61) | ALDH1A1TDP1CES2CES1GPR84 | |
| Methyl Isobutyl Ketone SCHEMBL28201028 | 0.88 | ALDH1A1 (0.54) | ALDH1A1TDP1CES2CES1GPR84 | |
| Dodecanoate SCHEMBL27819984 | 0.88 | GPR84 (0.65) | ALDH1A1TDP1GPR84LMNAMEN1 | |
| Methyl Isobutyl Ketone SCHEMBL9056069 | 0.87 | ALDH1A1 (0.82) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1916246-A2 | An improved process for the preparation of olmesartan medoxomil | Cadila Pharmaceuticals Limited (IN) | 2008-04-30 | — | — | EP | claimed |
| US-20240190882-A1 | Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile | PRINCIPIA BIOPHARMA INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-20230242505-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11667641-B2 | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile | PRINCIPIA BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230149400-A1 | METHODS AND COMPOSITIONSFOR TREATING VIRAL INFECTIONS | ACLARIS THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20210205313-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4,4-DIMETHYLPENT-2-ENENITRILE | PRINCIPIA BIOPHARMA INC. | 2021-07-08 | — | — | US | disclosed |
| US-20210206772-A1 | CRYSTALLINE FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4,4-DIMETHYLPENT-2-ENENITRILE | PRINCIPIA BIOPHARMA INC. | 2021-07-08 | — | — | US | disclosed |
| EP-1856111-B1 | Purification of mupirocin | SYNGEN BIOTECH CO LTD (TW) | 2014-01-29 | — | — | EP | disclosed |
| CN-101679449-B | Process for producing trans-dibenzoxenopyrrole compound and intermediate therefor | SUMITOMO CHEMICAL CO | 2012-05-30 | — | — | CN | disclosed |
| CN-101679449-A | Process for producing trans-dibenzoxenopyrrole compound and intermediate therefor | SUMITOMO CHEMICAL CO | 2010-03-24 | — | — | CN | disclosed |
| US-7619102-B2 | Purification of mupirocin | AXELLIA PHARMACEUTICALS APS (DK) | 2009-11-17 | — | — | US | disclosed |
| US-20080234503-A1 | Purification of Mupirocin | ALPHARMA APS (DK) | 2008-09-25 | — | — | US | disclosed |
| EP-1856111-A1 | PURIFICATION OF MUPIROCIN | Alpharma APS (DK) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006087237-A1 | PURIFICATION OF MUPIROCIN | ALPHARMA APS (DK) | 2006-08-24 | — | — | WO | disclosed |
| EP-1147210-A4 | PROCESS FOR THE ISOLATION OF PSEUDOMONIC ACID A FROM PSEUDOMONIC ACID COMPLEX-CONTAINING CULTURE BROTH | BIOGAL GYOGYSZERGYAR (HU) | 2004-06-02 | — | — | EP | disclosed |
| EP-1147210-A1 | PROCESS FOR THE ISOLATION OF PSEUDOMONIC ACID A FROM PSEUDOMONIC ACID COMPLEX-CONTAINING CULTURE BROTH | Teva Gyogyszergyar Reszvenytarsasag (HU) | 2001-10-24 | — | — | EP | disclosed |
| US-6245921-B1 | SOLVENT EXTRACTION FROM A CULTURE OF PSEUDOMONAS BACTERIUM USING CHLORINATED HYDROCARBON OR ISOBUTYL ACETATE; PURIFICATION, HIGH RECOVERY YIELD | BIOGAL GYOGYSZERGYAR RT. (HU) | 2001-06-12 | — | — | US | disclosed |
| WO-2000046388-A1 | PROCESS FOR THE ISOLATION OF PSEUDOMONIC ACID A FROM PSEUDOMONIC ACID COMPLEX-CONTAINING CULTURE BROTH | BIOGAL GYOGYSZERGYAR RT. (HU) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242505-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK6, MAPK1, MAPK8 | ALDH1A1 4227/4885TDP1 248/4885CES2 4598/4885 |
| US-20210205313-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4,4-DIMETHYLPENT-2-ENENITRILE | TYR, DPM1, POLR1C | ALDH1A1 283/4885TDP1 573/4885CES2 2591/4885 |
| US-20210206772-A1 | CRYSTALLINE FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4,4-DIMETHYLPENT-2-ENENITRILE | BTK, LCK, SYK | ALDH1A1 4588/4885TDP1 727/4885CES2 3472/4885 |
| US-20230149400-A1 | METHODS AND COMPOSITIONSFOR TREATING VIRAL INFECTIONS | MAVS, CCL11, SARS1 | ALDH1A1 2694/4885TDP1 4238/4885CES2 943/4885 |
| US-20240190882-A1 | Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile | BTK, LCK, SYK | ALDH1A1 4588/4885TDP1 727/4885CES2 3472/4885 |
| US-11667641-B2 | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile | BTK, LCK, SYK | ALDH1A1 4595/4885TDP1 746/4885CES2 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.